• LinkedIn
SFL Regulatory Affairs & Scientific Communication Ltd.
  • About SFL
    • Why SFL
    • Team
    • Associations
    • History
    • Awards
    • Ethics
  • Services
    • Regulatory Affairs
    • Quality Assurance & GxP Compliance
    • Medical Affairs & Communication
    • Market Access & Reimbursement
    • Public Affairs & Regulatory Intelligence
    • Medical Devices, Combination Products and IVDs
    • Pharmacovigilance & Clinical Safety
    • Supply Chains of Medicines and Devices
    • Legal & Healthcare Compliance
    • Swiss Support
    • UK Support
    • Clinical Trials support
  • Clients
    • Testimonials
    • Cases
  • Trainings
    • Customized training
    • Webinars
  • News
    • News
    • Newsletter
  • Careers
  • Contact
  • Search
  • Menu Menu

SFL invites you to a free webinar on Orphan Drug Designation Application in the EU 30 January 2020, 4 – 5 pm CET

We are pleased to announce that Daniela Kenzelmann Broz, SFL Director Medical Affairs and Julien Gaudias, SFL Director Regulatory Affairs will present a free webinar entitled “Orphan Drug Designation Application in the EU” (30 January 2020, 4 to 5 pm CET).

The webinar, moderated by Anja Bührer, SFL Head Regulatory Affairs, will provide an overview of key aspects regarding the application for Orphan Drug Designation in the EU – relevant to any company developing orphan drugs.

Register now to take advantage of the expert insights provided by the SFL team on this highly relevant topic and find out the most important considerations for preparing an Orphan Drug Application in the EU.

SFL provides strategic and operational support for both medical affairs and regulatory projects, including pre- and post-authorization activities.

  • News
  • Newsletter

Switzerland – Main Office

SFL Regulatory Affairs & Scientific Communication GmbH
Aeschenvorstadt 52 | CH-4051 Basel
Email: office@sfl-services.com
Phone: +41 61 361 9443

© Copyright 2023 - SFL Regulatory Affairs & Scientific Communication GmbH | Terms and Conditions | Privacy Statement | Cookies Policy
Scroll to top